[go: up one dir, main page]

CR20200241A - Ligandos de psma para la formación de imágenes y endoradioterapia - Google Patents

Ligandos de psma para la formación de imágenes y endoradioterapia

Info

Publication number
CR20200241A
CR20200241A CR20200241A CR20200241A CR20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A CR 20200241 A CR20200241 A CR 20200241A
Authority
CR
Costa Rica
Prior art keywords
psma
imaging
endoradiotherapy
links
compounds
Prior art date
Application number
CR20200241A
Other languages
English (en)
Inventor
Alexander Schmidt
Hans-Jürgen Wester
Mara Parzinger
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of CR20200241A publication Critical patent/CR20200241A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. También se porporcionan usos médicos de dichos compuestos.
CR20200241A 2017-12-11 2018-12-11 Ligandos de psma para la formación de imágenes y endoradioterapia CR20200241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206510 2017-12-11
PCT/EP2018/084399 WO2019115547A1 (en) 2017-12-11 2018-12-11 Psma ligands for imaging and endoradiotherapy

Publications (1)

Publication Number Publication Date
CR20200241A true CR20200241A (es) 2020-09-21

Family

ID=60654872

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200241A CR20200241A (es) 2017-12-11 2018-12-11 Ligandos de psma para la formación de imágenes y endoradioterapia

Country Status (32)

Country Link
US (2) US11497819B2 (es)
EP (3) EP3723815B1 (es)
JP (3) JP7317375B2 (es)
KR (1) KR20200097690A (es)
CN (2) CN116617421A (es)
AU (2) AU2018382479B2 (es)
BR (1) BR112020011727A2 (es)
CA (1) CA3078104A1 (es)
CL (1) CL2020001542A1 (es)
CR (1) CR20200241A (es)
CU (1) CU24677B1 (es)
DK (2) DK3723815T3 (es)
EC (1) ECSP20029142A (es)
ES (2) ES2914832T3 (es)
FI (1) FI4008359T3 (es)
HR (2) HRP20241453T1 (es)
HU (2) HUE069034T2 (es)
IL (2) IL313103B1 (es)
JO (1) JOP20200135A1 (es)
LT (2) LT4008359T (es)
MX (2) MX2020005430A (es)
PE (1) PE20210456A1 (es)
PL (1) PL3723815T3 (es)
PT (2) PT3723815T (es)
RS (2) RS63279B1 (es)
SG (1) SG11202002965WA (es)
SI (1) SI3723815T1 (es)
SM (1) SMT202400439T1 (es)
TN (1) TN2020000072A1 (es)
UA (1) UA126413C2 (es)
WO (1) WO2019115547A1 (es)
ZA (1) ZA202003472B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4008359T (lt) 2017-12-11 2024-12-27 Technische Universität München Psma ligandai, skirti vizualizavimui ir endoradioterapijai
JP7549585B2 (ja) * 2019-01-30 2024-09-11 テクニシェ ユニバーシタット ミュンヘン がん診断用画像化剤
HUE063038T2 (hu) * 2019-01-30 2023-12-28 Univ Muenchen Tech Kettõs üzemmódú PSMA-kötõ radionyomjelzõk és terápiás szerek
AU2020296488A1 (en) 2019-06-21 2022-01-20 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
CN113354707A (zh) * 2021-06-07 2021-09-07 苏州思萃同位素技术研究所有限公司 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品
WO2023173074A2 (en) * 2022-03-10 2023-09-14 The Research Foundation For The State University Of New York Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125048A2 (en) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
CN102171187B (zh) * 2008-08-01 2017-07-28 约翰.霍普金斯大学 Psma‑结合剂及其用途
WO2010135431A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
ES2977715T3 (es) * 2013-10-18 2024-08-29 Novartis Ag Inhibidores marcados de antígeno prostático específico de membrana (psma), su uso como agentes formadores de imágenes y agentes farmacéuticos para el tratamiento de cáncer de próstata
CN106660943B (zh) 2014-05-06 2020-03-17 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
RU2749399C2 (ru) * 2016-03-22 2021-06-09 Дзе Джонс Хопкинс Юниверсити Простатический специфический мембранный антиген-таргетные высокоаффинные средства для эндорадиотерапии рака предстательной железы
LT4008359T (lt) 2017-12-11 2024-12-27 Technische Universität München Psma ligandai, skirti vizualizavimui ir endoradioterapijai
DK3724176T3 (da) 2017-12-11 2022-04-04 Helsinn Healthcare Sa Fumaratsalt af (r)-3-(1-(2,3-dichlor-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluorethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, fremgangsmåder til fremstilling og anvendelser deraf
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物

Also Published As

Publication number Publication date
US20230122957A1 (en) 2023-04-20
ES2997266T3 (en) 2025-02-14
EP4464341A2 (en) 2024-11-20
IL313103B1 (en) 2025-03-01
KR20200097690A (ko) 2020-08-19
IL313103A (en) 2024-07-01
ECSP20029142A (es) 2020-09-30
JP7317375B2 (ja) 2023-07-31
PT3723815T (pt) 2022-05-30
EP4464341A3 (en) 2025-01-22
ZA202003472B (en) 2022-06-29
LT4008359T (lt) 2024-12-27
PL3723815T3 (pl) 2022-07-18
JP7572080B2 (ja) 2024-10-23
IL274072B2 (en) 2024-11-01
HRP20241453T1 (hr) 2024-12-20
FI4008359T3 (fi) 2024-11-11
HUE069034T2 (hu) 2025-02-28
IL274072B1 (en) 2024-07-01
AU2018382479B2 (en) 2024-11-07
WO2019115547A1 (en) 2019-06-20
JP2021505532A (ja) 2021-02-18
IL274072A (en) 2020-06-30
CN111182927B (zh) 2023-07-21
MX2023005053A (es) 2023-05-17
UA126413C2 (uk) 2022-09-28
TN2020000072A1 (en) 2022-01-06
ES2914832T3 (es) 2022-06-16
DK4008359T3 (da) 2024-10-14
CL2020001542A1 (es) 2020-10-02
PE20210456A1 (es) 2021-03-08
EP4008359B1 (en) 2024-09-11
RU2020116158A (ru) 2022-01-13
AU2018382479A1 (en) 2020-04-16
US20200297876A1 (en) 2020-09-24
SG11202002965WA (en) 2020-04-29
JOP20200135A1 (ar) 2020-06-02
EP3723815B1 (en) 2022-04-20
AU2025200837A1 (en) 2025-02-27
MX2020005430A (es) 2020-08-27
US11497819B2 (en) 2022-11-15
RS63279B1 (sr) 2022-06-30
DK3723815T3 (da) 2022-07-11
RS66086B1 (sr) 2024-11-29
CA3078104A1 (en) 2019-06-20
CU24677B1 (es) 2023-09-07
SI3723815T1 (sl) 2022-07-29
EP4008359A1 (en) 2022-06-08
PT4008359T (pt) 2024-10-25
JP2025011169A (ja) 2025-01-23
HUE059083T2 (hu) 2022-10-28
CN111182927A (zh) 2020-05-19
CU20200052A7 (es) 2021-03-11
CN116617421A (zh) 2023-08-22
EP3723815A1 (en) 2020-10-21
JP2023139063A (ja) 2023-10-03
HRP20220764T1 (hr) 2022-09-16
LT3723815T (lt) 2022-07-25
SMT202400439T1 (it) 2024-11-15
BR112020011727A2 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
ECSP20029142A (es) Ligandos de psma para la formación de imágenes y endorradioterapia
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
DOP2018000280A (es) Compuestos moduladores de fxr (nr1h4)
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
CL2023002048A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos
PE20171041A1 (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
PE20181367A1 (es) Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
BR112016025470A2 (pt) ?hdl terapêutico?
MY194484A (en) Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
CO2018003726A2 (es) Inhibidores marcados con 18f mejorados del antígeno de membrana específica de próstata (psma) y su uso como agentes de formación de imágenes para cáncer de próstata
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2014013678A (es) Agentes para neutralizacion de influenza.
MX2017011194A (es) Anticuerpos, usos y métodos.
AR113543A2 (es) Ésteres de oxaborol y sus usos
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana